10 July 2012

Melasma

Melasma Blemish
http://med-docs.creighton.edu

Nonoperative Facial Rejuvenation
Andrew Coughlin M.D., Raghu Athre M.D.
http://www.utmb.edu/

Disturbances of Pigmentation
Boris Ioffe, D.O.
http://www.atsu.edu/

Cosmetic Dermatology in Primary Care
Jenifer Hammond MD, Anita Wolfe
http://www.ucdenver.org/

Integumentary System
http://www.midlandstech.edu

Contraception
Elaine Stauble MD
http://louisville.edu

Melasma
http://www.med.unc.edu

Integumentary System
George Ann Daniels MS, RN
http://www.rsu.edu/

Contraception
Elizabeth Dehmer
http://www.med.unc.edu

Oral Contraceptive Pill: A General Overview
Kristy Van Kirk
http://www.fammed.washington.edu

Chemical Peeling
Michael E. Decherd, MD, Karen H. Calhoun, MD
http://www2.utmb.edu

Facial Chemical Peels
Jean Paul Font, MD, David C. Teller, MD
http://www.utmb.edu

Mucinoses, Lichen Planus and Related Conditions
http://www.atsu.edu


289 Published articles on Melasma
1. Sarkar R, Chugh S, Garg VK. Newer and upcoming therapies for melasma. Indian J; Dermatol Venereol Leprol. 2012 Jul;78(4):417-28.
2. Kang HY, Bahadoran P. Application of in vivo reflectance confocal microscopy; in melasma classification. J Am Acad Dermatol. 2012 Jul;67(1):157.
3. Kim NH, Cheong KA, Lee TR, Lee AY. PDZK1 Upregulation in Estrogen-Related; Hyperpigmentation in Melasma. J Invest Dermatol. 2012 Jun 14. doi:; 10.1038/jid.2012.175. [Epub ahead of print]
4. Vachiramon V, Suchonwanit P, Thadanipon K. Melasma in men. J Cosmet Dermatol. ; 2012 Jun;11(2):151-7. doi. 10.1111/j.1473-2165.2012.00613.x.
5. Kauvar AN. The evolution of melasma therapy. targeting melanosomes using; low-fluence q-switched neodymium-doped yttrium aluminium garnet lasers. Semin; Cutan Med Surg. 2012 Jun;31(2):126-32.
6. Purim KS, Avelar MF. [Photoprotection, melasma and quality of life in pregnant; women]. Rev Bras Ginecol Obstet. 2012 May;34(5):228-34. Portuguese.
7. Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma. a review of; the recent literature. Dermatol Surg. 2012 Jul;38(7 Pt 1):971-84. doi:; 10.1111/j.1524-4725.2012.02435.x. Epub 2012 May 14.
8. Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, Pan L. Treatment of Melasma With Oral ; Administration of Tranexamic Acid. Aesthetic Plast Surg. 2012 May 3. [Epub ahead ; of print]
9. Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the; Lumixyl topical brightening system. J Drugs Dermatol. 2012 May;11(5):660-2.;
10. Ayuthaya PK, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid; for the treatment of melasma in Asians. a double-blind randomized controlled; clinical trial. J Cosmet Laser Ther. 2012 Jun;14(3):150-4.
11. Kar HK, Gupta L, Chauhan A. A comparative study on efficacy of high and low; fluence Q-switched Nd:YAG laser and glycolic acid peel in melasma. Indian J; Dermatol Venereol Leprol. 2012 Mar-Apr;78(2):165-71.
12. Tourlaki A, Galimberti MG, Pellacani G, Bencini PL. Combination of fractional; erbium-glass laser and topical therapy in melasma resistant to triple-combination; cream. J Dermatolog Treat. 2012 Apr 12. [Epub ahead of print]
13. Hong SP, Han SS, Choi SJ, Kim MS, Won CH, Lee MW, Choi JH, Moon KC, Kim YJ,; Chang SE. Split-face comparative study of 1550 nm fractional photothermolysis and; trichloroacetic acid 15% chemical peeling for facial melasma in Asian skin. J; Cosmet Laser Ther. 2012 Apr;14(2):81-6. Epub 2012 Feb 28.
14. Sobhi RM, Sobhi AM. A single-blinded comparative study between the use of; glycolic acid 70% peel and the use of topical nanosome vitamin C iontophoresis in; the treatment of melasma. J Cosmet Dermatol. 2012 Mar;11(1):65-71. doi:; 10.1111/j.1473-2165.2011.00599.x.
15. Panda S. Melasma study. methodological problems. Indian J Dermatol. 2011; Nov;56(6):772-3.
16. Kauvar AN. Successful treatment of melasma using a combination of; microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med. 2012; Feb;44(2):117-24. doi. 10.1002/lsm.21156. Epub 2012 Jan 3.
17. Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid; on melasma. a clinical trial with histological evaluation. J Eur Acad Dermatol; Venereol. 2012 Feb 13. doi. 10.1111/j.1468-3083.2012.04464.x. [Epub ahead of; print]
18. Jang YH, Sim JH, Kang HY, Kim YC, Lee ES. The histopathological; characteristics of male melasma. comparison with female melasma and lentigo. J Am; Acad Dermatol. 2012 Apr;66(4):642-9. Epub 2012 Jan 30.
19. Lieu TJ, Pandya AG. Melasma quality of life measures. Dermatol Clin. 2012; Apr;30(2):269-80, viii. Review.
20. Situm M, Kolić M, Bolanca Z, Ljubicić I, Misanović B. Melasma--updated; treatments. Coll Antropol. 2011 Sep;35 Suppl 2:315-8. Review.
21. Tamega AD, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical; patterns and epidemiological characteristics of facial melasma in Brazilian; women. J Eur Acad Dermatol Venereol. 2012 Jan 3. doi:; 10.1111/j.1468-3083.2011.04430.x. [Epub ahead of print]
22. Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K. Measuring; melasma patients' quality of life using willingness to pay and time trade-off; methods in Thai population. BMC Dermatol. 2011 Dec 19;11:16.
23. Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and; hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011; Dec;10(4):282-7. doi. 10.1111/j.1473-2165.2011.00580.x.
24. Park GH, Lee JH, Choi JR, Chang SE. The degree of erythema in melasma lesion ; is associated with the severity of disease and the response to the low-fluence; Q-switched 1064-nm Nd:YAG laser treatment. J Dermatolog Treat. 2012 Apr 12. [Epub; ahead of print]
25. Faghihi G, Shahingohar A, Siadat AH. Comparison between 1% tretinoin peeling ; versus 70% glycolic acid peeling in the treatment of female patients with; melasma. J Drugs Dermatol. 2011 Dec;10(12):1439-42.
26. Cho HH, Choi M, Cho S, Lee JH. Role of oral tranexamic acid in melasma; patients treated with IPL and low fluence QS Nd:YAG laser. J Dermatolog Treat.; 2011 Dec 27. [Epub ahead of print]
27. Polder KD, Bruce S. Treatment of melasma using a novel 1,927-nm fractional; thulium fiber laser. a pilot study. Dermatol Surg. 2012 Feb;38(2):199-206. doi:; 10.1111/j.1524-4725.2011.02178.x. Epub 2011 Oct 10.
28. Lee DJ, Lee J, Ha J, Park KC, Ortonne JP, Kang HY. Defective barrier function; in melasma skin. J Eur Acad Dermatol Venereol. 2011 Nov 12. doi:; 10.1111/j.1468-3083.2011.04337.x. [Epub ahead of print]
29. Tsilika K, Levy JL, Kang HY, Duteil L, Khemis A, Hughes R, Passeron T,; Ortonne JP, Bahadoran P. A pilot study using reflectance confocal microscopy; (RCM) in the assessment of a novel formulation for the treatment of melasma. J; Drugs Dermatol. 2011 Nov;10(11):1260-4.
30. Alvin G, Catambay N, Vergara A, Jamora MJ. A comparative study of the safety ; and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical; treatment for melasma. a randomized, single-blind, placebo-controlled trial. J; Drugs Dermatol. 2011 Sep 1;10(9):1025-31.
31. Brown AS, Hussain M, Goldberg DJ. Treatment of melasma with low fluence,; large spot size, 1064-nm Q-switched neodymium-doped yttrium aluminum garnet; (Nd:YAG) laser for the treatment of melasma in Fitzpatrick skin types II-IV. J; Cosmet Laser Ther. 2011 Dec;13(6):280-2.
32. Sehgal VN, Verma P, Srivastava G, Aggarwal AK, Verma S. Melasma. treatment; strategy. J Cosmet Laser Ther. 2011 Dec;13(6):265-79. Review.
33. Park KY, Kim DH, Kim HK, Li K, Seo SJ, Hong CK. A randomized,; observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped; yttrium-aluminium-garnet laser plus 30% glycolic acid peel vs. laser monotherapy ; to treat melasma. Clin Exp Dermatol. 2011 Dec;36(8):864-70. doi:; 10.1111/j.1365-2230.2011.04150.x. Epub 2011 Oct 5.
34. Achar A, Rathi SK. Melasma. a clinico-epidemiological study of 312 cases.; Indian J Dermatol. 2011 Jul;56(4):380-2.
35. Celia C, Cilurzo F, Trapasso E, Cosco D, Fresta M, Paolino D. Ethosomes® and ; transfersomes® containing linoleic acid. physicochemical and technological; features of topical drug delivery carriers for the potential treatment of melasma; disorders. Biomed Microdevices. 2012 Feb;14(1):119-30.
36. Lee DJ, Park KC, Ortonne JP, Kang HY. Pendulous melanocytes. a characteristic; feature of melasma and how it may occur. Br J Dermatol. 2012 Mar;166(3):684-6.; doi. 10.1111/j.1365-2133.2011.10648.x. Epub 2012 Feb 6.
37. Passeron T, Fontas E, Kang HY, Bahadoran P, Lacour JP, Ortonne JP. Melasma; treatment with pulsed-dye laser and triple combination cream. a prospective,; randomized, single-blind, split-face study. Arch Dermatol. 2011; Sep;147(9):1106-8.
38. Sheth VM, Pandya AG. Melasma. a comprehensive update. part II. J Am Acad; Dermatol. 2011 Oct;65(4):699-714; quiz 715. Review.
39. Sheth VM, Pandya AG. Melasma. a comprehensive update. part I. J Am Acad; Dermatol. 2011 Oct;65(4):689-97; quiz 698. Review.
40. Gold MH, Biron J. Efficacy of a novel hydroquinone-free skin-brightening; cream in patients with melasma. J Cosmet Dermatol. 2011 Sep;10(3):189-96. doi:; 10.1111/j.1473-2165.2011.00573.x.
41. Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, Oros-Ovalle C,; Fuentes-Ahumada C, González FJ, Martínez-Ramírez JD, Moncada B. A Double-Blind,; Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the; Treatment of Melasma. Dermatol Res Pract. 2011;2011:379173. Epub 2011 Jul 21.;
42. Na SY, Cho S, Lee JH. Better clinical results with long term benefits in; melasma patients. J Dermatolog Treat. 2011 Jul 31. [Epub ahead of print] PubMed; PMID. 21801110.
43. Sabancilar E, Aydin F, Bek Y, Ozden MG, Ozcan M, Senturk N, Canturk T,; Turanli AY. Treatment of melasma with a depigmentation cream determined with; colorimetry. J Cosmet Laser Ther. 2011 Oct;13(5):255-9.
44. Arellano I, Cestari T, Ocampo-Candiani J, Azulay-Abulafia L, Bezerra Trindade; Neto P, Hexsel D, Machado-Pinto J, Muñoz H, Rivitti-Machado MC, Sittart JA,; Trindade de Almeida AR, Rego V, Paliargues F, Marques-Hassun K. Preventing; melasma recurrence. prescribing a maintenance regimen with an effective triple; combination cream based on long-standing clinical severity. J Eur Acad Dermatol; Venereol. 2012 May;26(5):611-8. doi. 10.1111/j.1468-3083.2011.04135.x. Epub 2011 ; May 31.
45. Zhou X, Gold MH, Lu Z, Li Y. Efficacy and safety of Q-switched 1,064-nm; neodymium-doped yttrium aluminum garnet laser treatment of melasma. Dermatol; Surg. 2011 Jul;37(7):962-70. doi. 10.1111/j.1524-4725.2011.02001.x. Epub 2011 May; 26.
46. Jang WS, Lee CK, Kim BJ, Kim MN. Efficacy of 694-nm Q-switched ruby; fractional laser treatment of melasma in female Korean patients. Dermatol Surg.; 2011 Aug;37(8):1133-40. doi. 10.1111/j.1524-4725.2011.02018.x. Epub 2011 May 17. ;
47. Karsai S, Fischer T, Pohl L, Schmitt L, Buhck H, Jünger M, Raulin C. Is; non-ablative 1550-nm fractional photothermolysis an effective modality to treat; melasma? Results from a prospective controlled single-blinded trial in 51; patients. J Eur Acad Dermatol Venereol. 2012 Apr;26(4):470-6. doi:; 10.1111/j.1468-3083.2011.04100.x. Epub 2011 May 14.
48. Kang HY, Suzuki I, Lee DJ, Ha J, Reiniche P, Aubert J, Deret S, Zugaj D,; Voegel JJ, Ortonne JP. Transcriptional profiling shows altered expression of wnt ; pathway- and lipid metabolism-related genes as well as melanogenesis-related; genes in melasma. J Invest Dermatol. 2011 Aug;131(8):1692-700. doi:; 10.1038/jid.2011.109. Epub 2011 May 12.
49. Perez M, Luke J, Rossi A. Melasma in Latin Americans. J Drugs Dermatol. 2011 ; May;10(5):517-23.
50. Barysch MJ, Rümmelein B, Kolm I, Karpova MB, Schönewolf N, Bogdan Allemann I,; Dummer R. Split-face study of melasma patients treated with non-ablative; fractionated photothermolysis (1540 nm). J Eur Acad Dermatol Venereol. 2012; Apr;26(4):423-30. doi. 10.1111/j.1468-3083.2011.04086.x. Epub 2011 Apr 27. PubMed; PMID. 21521377.
51. Badri T, Hammami H, Benmously R, Mokhtar I, Fenniche S. [Is there any place; for laser devices in the treatment of melasma?]. Ann Dermatol Venereol.; 2011;138(4):319-20. Epub 2011 Feb 1. Review. French.
52. Majid I. Mometasone-based triple combination therapy in melasma. is it really; safe? Indian J Dermatol. 2010 Oct;55(4):359-62.
53. Sharma P, Pai HS, Pai GS, Kuruvila M, Kolar R. Response to narrow-band; UVB--vitiligo-melasma versus vitiligo. a comparative study. Am J Clin Dermatol.; 2011 Apr 1;12(2):127-32. doi. 10.2165/11537120-000000000-00000.
54. Godse KV, Sakhia J. Triple combination and glycolic acid peels in melasma in ; Indian patients. J Cosmet Dermatol. 2011 Mar;10(1):68-9. doi:; 10.1111/j.1473-2165.2010.00540.x.
55. Liu H, Lin Y, Nie X, Chen S, Chen X, Shi B, Tian H, Shi Z, Yu M, Zhang D,; Yang B, Wang G, Wu M, Zhang F. Histological classification of melasma with; reflectance confocal microscopy. a pilot study in Chinese patients. Skin Res; Technol. 2011 Nov;17(4):398-403. doi. 10.1111/j.1600-0846.2011.00517.x. Epub 2011; Feb 21.
56. Torres-Álvarez B, Mesa-Garza IG, Castanedo-Cázares JP, Fuentes-Ahumada C,; Oros-Ovalle C, Navarrete-Solis J, Moncada B. Histochemical and; immunohistochemical study in melasma. evidence of damage in the basal membrane.; Am J Dermatopathol. 2011 May;33(3):291-5.
57. Goldman MP, Gold MH, Palm MD, Colón LE, Preston N, Johnson LA, Gottschalk RW.; Sequential treatment with triple combination cream and intense pulsed light is; more efficacious than sequential treatment with an inactive (control) cream and; intense pulsed light in patients with moderate to severe melasma. Dermatol Surg. ; 2011 Feb;37(2):224-33. doi. 10.1111/j.1524-4725.2010.01849.x. Epub 2011 Jan 26.;
58. Pratchyapruit W, Vashrangsi N, Sindhavananda J, Tagami H. Instrumental; analysis of the pattern of improvement and that of recurrence of melasma in Thai ; females treated with Kligman-Willis triple combination therapy. confirmation by; using its two different formulae. Skin Res Technol. 2011 May;17(2):226-33. doi:; 10.1111/j.1600-0846.2010.00489.x. Epub 2011 Jan 24.
59. Kroon MW, Wind BS, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Bos JD, ; Wolkerstorfer A. Nonablative 1550-nm fractional laser therapy versus triple; topical therapy for the treatment of melasma. a randomized controlled pilot; study. J Am Acad Dermatol. 2011 Mar;64(3):516-23. Epub 2011 Jan 20.
60. Draelos ZD. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet; laser for melasma with pre- or post-treatment triple combination cream. Dermatol ; Surg. 2011 Jan;37(1):126-7. doi. 10.1111/j.1524-4725.2010.01835.x. Erratum in:; Dermatol Surg. 2011 Jan;37(1):126.
61. Fabbrocini G, De Vita V, Fardella N, Pastore F, Annunziata MC, Mauriello MC, ; Monfrecola A, Cameli N. Skin needling to enhance depigmenting serum penetration; in the treatment of melasma. Plast Surg Int. 2011;2011:158241. Epub 2011 Apr 7.;
62. Rendon M. Top-accessed article. glycolic Acid peels in the treatment of; melasma. Arch Dermatol. 2010 Dec 20;146(12):1439.
63. Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann; Dermatol. 2010 Nov;22(4):373-8. Epub 2010 Nov 5.
64. Costa A, Moisés TA, Cordero T, Alves CR, Marmirori J. Association of emblica,; licorice and belides as an alternative to hydroquinone in the clinical treatment ; of melasma. An Bras Dermatol. 2010 Oct;85(5):613-20.
65. Neeley MR, Pearce FB, Collawn SS. Successful treatment of malar dermal; melasma with a fractional ablative CO₂ laser in a patient with type V skin. J; Cosmet Laser Ther. 2010 Dec;12(6):258-60.
66. Yi X, Zhao G, Zhang H, Guan D, Meng R, Zhang Y, Yang Q, Jia H, Dou K, Liu C, ; Que F, Yin JQ. MITF-siRNA formulation is a safe and effective therapy for human; melasma. Mol Ther. 2011 Feb;19(2):362-71. Epub 2010 Nov 30.
67. Kodali S, Guevara IL, Carrigan CR, Daulat S, Blanco G, Boker A, Hynan LS,; Pandya AG. A prospective, randomized, split-face, controlled trial of salicylic; acid peels in the treatment of melasma in Latin American women. J Am Acad; Dermatol. 2010 Dec;63(6):1030-5.
68. Chan NP, Ho SG, Shek SY, Yeung CK, Chan HH. A case series of facial; depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for; skin rejuvenation and melasma. Lasers Surg Med. 2010 Oct;42(8):712-9. PubMed; PMID. 20848553.
69. Wind BS, Kroon MW, Meesters AA, Beek JF, van der Veen JP,; Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A. Non-ablative 1,550 nm fractional; laser therapy versus triple topical therapy for the treatment of melasma. a; randomized controlled split-face study. Lasers Surg Med. 2010 Sep;42(7):607-12.;
70. Katz TM, Glaich AS, Goldberg LH, Firoz BF, Dai T, Friedman PM. Treatment of; melasma using fractional photothermolysis. a report of eight cases with long-term; follow-up. Dermatol Surg. 2010 Aug;36(8):1273-80.
71. Kumari R, Thappa DM. Comparative study of trichloroacetic acid versus; glycolic acid chemical peels in the treatment of melasma. Indian J Dermatol; Venereol Leprol. 2010 Jul-Aug;76(4):447.
72. Jadotte YT, Schwartz RA. Melasma. insights and perspectives. Acta; Dermatovenerol Croat. 2010;18(2):124-9. Review.
73. Ghersetich I, Troiano M, Brazzini B, Arunachalam M, Lotti T. Melasma:; treatment with 10% tretinoin peeling mask. J Cosmet Dermatol. 2010; Jun;9(2):117-21.
74. Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma.; Cochrane Database Syst Rev. 2010 Jul 7;(7):CD003583. Review.
75. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. The Efficacy and Safety of ; 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma. A Randomized; Controlled Split-face Trial. Ann Dermatol. 2010 Feb;22(1):21-5. Epub 2010 Feb 28.;
76. Tadokoro T, Bonté F, Archambault JC, Cauchard JH, Neveu M, Ozawa K, Noguchi; F, Ikeda A, Nagamatsu M, Shinn S. Whitening efficacy of plant extracts including ; orchid extracts on Japanese female skin with melasma and lentigo senilis. J; Dermatol. 2010 Jun;37(6):522-30.
77. Miot LD, Miot HA, Polettini J, Silva MG, Marques ME. Morphologic changes and ; the expression of alpha-melanocyte stimulating hormone and melanocortin-1; receptor in melasma lesions. a comparative study. Am J Dermatopathol. 2010; Oct;32(7):676-82.
78. Misery L, Schmitt AM, Boussetta S, Rahhali N, Taieb C. Melasma. measure of; the impact on quality of life using the French version of MELASQOL after; cross-cultural adaptation. Acta Derm Venereol. 2010 May;90(3):331-2.
79. Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams; alone, CO2 fractional ablative resurfacing alone, or a combination of the two. a ; comparative study. J Drugs Dermatol. 2010 Apr;9(4):315-22.
80. Choi M, Choi JW, Lee SY, Choi SY, Park HJ, Park KC, Youn SW, Huh CH. Low-dose; 1064-nm Q-switched Nd:YAG laser for the treatment of melasma. J Dermatolog Treat.; 2010 Jul;21(4):224-8.
81. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. Efficacy and safety of; liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of; melasma. a randomized controlled split-face trial. J Dermatol. 2010; Apr;37(4):311-5.
82. Kang HY, Bahadoran P, Suzuki I, Zugaj D, Khemis A, Passeron T, Andres P,; Ortonne JP. In vivo reflectance confocal microscopy detects pigmentary changes in; melasma at a cellular level resolution. Exp Dermatol. 2010 Aug;19(8):e228-33.;
83. Lee HI, Lim YY, Kim BJ, Kim MN, Min HJ, Hwang JH, Song KY. Clinicopathologic ; efficacy of copper bromide plus/yellow laser (578 nm with 511 nm) for treatment; of melasma in Asian patients. Dermatol Surg. 2010 Jun;36(6):885-93. Epub 2010 May; 7.
84. Polnikorn N. Treatment of refractory melasma with the MedLite C6 Q-switched; Nd:YAG laser and alpha arbutin. a prospective study. J Cosmet Laser Ther. 2010; Jun;12(3):126-31.
85. Suh KS, Sung JY, Roh HJ, Jeon YS, Kim YC, Kim ST. Efficacy of the 1064-nm; Q-switched Nd:YAG laser in melasma. J Dermatolog Treat. 2011 Aug;22(4):233-8.; Epub 2010 May 6.
86. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, Nordlund JJ,; Rendon M, Taylor S, Gottschalk RW, Agim NG, Ortonne JP. Reliability assessment; and validation of the Melasma Area and Severity Index (MASI) and a new modified; MASI scoring method. J Am Acad Dermatol. 2011 Jan;64(1):78-83, 83.e1-2. Epub 2010; Apr 15.
87. Grimes PE, Bhawan J, Guevara IL, Colón LE, Johnson LA, Gottschalk RW, Pandya ; AG. Continuous therapy followed by a maintenance therapy regimen with a triple; combination cream for melasma. J Am Acad Dermatol. 2010 Jun;62(6):962-7. Epub; 2010 Apr 15.
88. Jeong SY, Shin JB, Yeo UC, Kim WS, Kim IH. Low-fluence Q-switched; neodymium-doped yttrium aluminum garnet laser for melasma with pre- or; post-treatment triple combination cream. Dermatol Surg. 2010 Jun;36(6):909-18.; Epub 2010 Apr 1.
89. Draelos ZD. Commentary. Low-Fluence Q-Switched Neodymium-Doped Yttrium; Aluminum Garnet Laser for Melasma with Pre- or Post-Treatment Triple Combination ; Cream. Dermatol Surg. 2010 Apr 1. [Epub ahead of print]
90. Ardigo M, Cameli N, Berardesca E, Gonzalez S. Characterization and evaluation; of pigment distribution and response to therapy in melasma using in vivo; reflectance confocal microscopy. a preliminary study. J Eur Acad Dermatol; Venereol. 2010 Nov;24(11):1296-303. doi. 10.1111/j.1468-3083.2010.03633.x. PubMed; PMID. 20337829.
91. Jang YH, Lee JY, Kang HY, Lee ES, Kim YC. Oestrogen and progesterone receptor; expression in melasma. an immunohistochemical analysis. J Eur Acad Dermatol; Venereol. 2010 Nov;24(11):1312-6. doi. 10.1111/j.1468-3083.2010.03638.x. PubMed; PMID. 20337826.
92. Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped; yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in; Asians. Dermatol Surg. 2010;36(1):76-87.
93. Guevara IL, Werlinger KD, Pandya AG. Tolerability and efficacy of a novel; formulation in the treatment of melasma. J Drugs Dermatol. 2010 Mar;9(3):215-8.;
94. Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense; pulsed light. Aesthetic Plast Surg. 2010 Aug;34(4):486-93. Epub 2010 Mar 12.;
95. Guinot C, Cheffai S, Latreille J, Dhaoui MA, Youssef S, Jaber K, Nageotte O, ; Doss N. Aggravating factors for melasma. a prospective study in 197 Tunisian; patients. J Eur Acad Dermatol Venereol. 2010 Sep;24(9):1060-9. Epub 2010 Feb 25. ;
96. Miot LD, Miot HA, Silva MG, Marques ME. [Physiopathology of melasma]. An Bras; Dermatol. 2009 Dec;84(6):623-35. Review. Portuguese.
97. Ilknur T, Biçak MU, Demirtaşoğlu M, Ozkan S. Glycolic acid peels versus amino; fruit acid peels in the treatment of melasma. Dermatol Surg. 2010; Apr;36(4):490-5. Epub 2010 Feb 19.
98. Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol.; 2009;54(4):303-9.
99. Young Kang H, Ortonne JP. Melasma update. Actas Dermosifiliogr. 2009 Dec;100 ; Suppl 2:110-3. Review.
100. Alikhan A, Daly M, Wu J, Balkrishnan R, Feldman SR. Cost-effectiveness of a ; hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating; melasma in the United States. J Dermatolog Treat. 2010 Sep;21(5):276-81. PubMed; PMID. 20055711.
101. Miot HA, Miot LD. Re. Topical 10% zinc sulfate solution for treatment of; melasma. Dermatol Surg. 2009 Dec;35(12):2050-1.
102. Godse KV. Triple combination of hydroquinone, tretinoin and mometasone; furoate with glycolic acid peels in melasma. Indian J Dermatol. 2009;54(1):92-3. ;
103. Safoury OS, Zaki NM, El Nabarawy EA, Farag EA. A study comparing chemical; peeling using modified Jessner's solution and 15% trichloroacetic Acid versus 15%; trichloroacetic acid in the treatment of melasma. Indian J Dermatol.; 2009;54(1):41-5.
104. Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men. a clinical,; aetiological and histological study. J Eur Acad Dermatol Venereol. 2010; Jul;24(7):768-72. Epub 2009 Dec 15.
105. Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in; melasma. Pigment Cell Melanoma Res. 2010 Feb;23(1):84-92. Epub 2009 Dec 4. PubMed; PMID. 19968822.
106. Azzam OA, Leheta TM, Nagui NA, Shaarawy E, Hay RM, Hilal RF. Different; therapeutic modalities for treatment of melasma. J Cosmet Dermatol. 2009; Dec;8(4):275-81.
107. Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm; Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol. 2009; Dec;34(8):e847-50. Epub 2009 Oct 10.
108. Sarvjot V, Sharma S, Mishra S, Singh A. Melasma. a clinicopathological study; of 43 cases. Indian J Pathol Microbiol. 2009 Jul-Sep;52(3):357-9.
109. Lee HS, Won CH, Lee DH, An JS, Chang HW, Lee JH, Kim KH, Cho S, Chung JH.; Treatment of melasma in Asian skin using a fractional 1,550-nm laser. an open; clinical study. Dermatol Surg. 2009 Oct;35(10):1499-504. Epub 2009 Aug 5.
110. Hantash BM, Jimenez F. A split-face, double-blind, randomized and; placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of ; recalcitrant melasma. J Drugs Dermatol. 2009 Aug;8(8):732-5.
111. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized,; double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E ; for melasma among Filipino women. Int J Dermatol. 2009 Aug;48(8):896-901.
112. Tirado-Sánchez A, Santamaría-Román A, Ponce-Olivera RM. Efficacy of dioic; acid compared with hydroquinone in the treatment of melasma. Int J Dermatol. 2009; Aug;48(8):893-5.
113. Cestari T, Arellano I, Hexsel D, Ortonne JP; Latin American Pigmentary; Disorders Academy. Melasma in Latin America. options for therapy and treatment; algorithm. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):760-72. Review. PubMed; PMID. 19646135.
114. Barolet D, Lussier I, Mery S, Merial-Kieny C. Beneficial effects of spraying; low mineral content thermal spring water after fractional photothermolysis in; patients with dermal melasma. J Cosmet Dermatol. 2009 Jun;8(2):114-8. PubMed; PMID. 19527335.
115. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, Hexsel D, ; Im S, Lim J, Lui H, Pandya A, Picardo M, Rendon M, Taylor S, Van Der Veen JP,; Westerhof W. A global survey of the role of ultraviolet radiation and hormonal; influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009; Nov;23(11):1254-62. Epub 2009 May 19.
116. Chung WK, Yang JH, Lee DW, Chang SE, Lee MW, Choi JH, Moon KC. Paradoxical; darkening of unperceived tattoo ink after relatively low fluence from a; Q-switched Nd:YAG (1064-nm) laser in the course of treatment for melasma. Clin; Exp Dermatol. 2009 Dec;34(8):e555-7. Epub 2009 May 26.
117. Moncada B, Sahagún-Sánchez LK, Torres-Alvarez B, Castanedo-Cázares JP,; Martínez-Ramírez JD, González FJ. Molecular structure and concentration of; melanin in the stratum corneum of patients with melasma. Photodermatol; Photoimmunol Photomed. 2009 Jun;25(3):159-60.
118. Bak H, Lee HJ, Chang SE, Choi JH, Kim MN, Kim BJ. Increased expression of; nerve growth factor receptor and neural endopeptidase in the lesional skin of; melasma. Dermatol Surg. 2009 Aug;35(8):1244-50. Epub 2009 May 12.
119. Salem A, Gamil H, Ramadan A, Harras M, Amer A. Melasma. treatment; evaluation. J Cosmet Laser Ther. 2009 Sep;11(3):146-50.
120. Wang HW, Liu KY. [Efficacy and safety of low-energy QS Nd:YAG and QS; alexandrite laser for melasma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009; Feb;31(1):45-7. Chinese.
121. Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical efficacy of 25% L-ascorbic; acid (C'ensil) in the treatment of melasma. J Cutan Med Surg. 2009; Mar-Apr;13(2):74-81.
122. Wanitphakdeedecha R, Manuskiatti W, Siriphukpong S, Chen TM. Treatment of; melasma using variable square pulse Er:YAG laser resurfacing. Dermatol Surg. 2009; Mar;35(3):475-81; discussion 481-2. Epub 2009 Feb 22.
123. Kim MJ, Kim JS, Cho SB. Punctate leucoderma after melasma treatment using; 1064-nm Q-switched Nd:YAG laser with low pulse energy. J Eur Acad Dermatol; Venereol. 2009 Aug;23(8):960-2. Epub 2009 Jan 13.
124. Jo HY, Kim CK, Suh IB, Ryu SW, Ha KS, Kwon YG, Kim YM. Co-localization of; inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of; patients with melasma. J Dermatol. 2009 Jan;36(1):10-6.
125. Kim SW, Yoon HS. Tamoxifen-induced melasma in a postmenopausal woman. J Eur ; Acad Dermatol Venereol. 2009 Oct;23(10):1199-200. Epub 2009 Feb 2.
126. Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Arcury; TA. The prevalence of melasma and its association with quality of life in adult; male Latino migrant workers. Int J Dermatol. 2009 Jan;48(1):22-6.
127. Rendon M, Cardona LM, Bussear EW, Benitez AL, Colón LE, Johnson LA.; Successful treatment of moderate to severe melasma with triple-combination cream ; and glycolic acid peels. a pilot study. Cutis. 2008 Nov;82(5):372-8.
128. Ertam I, Mutlu B, Unal I, Alper S, Kivçak B, Ozer O. Efficiency of ellagic; acid and arbutin in melasma. a randomized, prospective, open-label study. J; Dermatol. 2008 Sep;35(9):570-4.
129. Lee GS. Intravenous vitamin C in the treatment of post-laser; hyperpigmentation for melasma. a short report. J Cosmet Laser Ther. 2008; Dec;10(4):234-6.
130. Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6; Q-switched Nd:YAG laser. two case reports. J Cosmet Laser Ther. 2008; Sep;10(3):167-73.
131. Zanieri F, Assad GB, Campolmi P, Lotti T. Melasma. successful treatment with; pidobenzone 4% (K5lipogel). Dermatol Ther. 2008 Jul;21 Suppl 1:S18-9. PubMed; PMID. 18727811.
132. Dogramaci AC, Havlucu DY, Inandi T, Balkrishnan R. Validation of a melasma; quality of life questionnaire for the Turkish language. the MelasQoL-TR study. J ; Dermatolog Treat. 2009;20(2):95-9.
133. Adalatkhah H, Sadeghi-bazargani H, Amini-sani N, Zeynizadeh S. Melasma and; its association with different types of nevi in women. a case-control study. BMC ; Dermatol. 2008 Aug 5;8:3.
134. Kasraee B, Safaee Ardekani GH, Parhizgar A, Handjani F, Omrani GR, Samani M,; Nikbakhsh M, Tanideh N, Eshraghian A, Sorg O, Saurat JH. Safety of topical; methimazole for the treatment of melasma. Transdermal absorption, the effect on; thyroid function and cutaneous adverse effects. Skin Pharmacol Physiol.; 2008;21(6):300-5. Epub 2008 Jul 31.
135. Hexsel D, Rodrigues TC, Dal'Forno T, Zechmeister-Prado D, Lima MM. Melasma; and pregnancy in southern Brazil. J Eur Acad Dermatol Venereol. 2009; Mar;23(3):367-8. Epub 2008 Jul 7.
136. Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, Tay YK,; Legarda-Montinola F, Tsai RY, Tsai TH, Shek S, Kerrouche N, Thomas G,; Verallo-Rowell V. A randomized controlled trial of the efficacy and safety of a; fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%,; tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with; moderate to severe melasma. Br J Dermatol. 2008 Sep;159(3):697-703. Epub 2008 Jul; 4.
137. Sharquie KE, Al-Mashhadani SA, Salman HA. Topical 10% zinc sulfate solution ; for treatment of melasma. Dermatol Surg. 2008 Oct;34(10):1346-9. Epub 2008 Jun; 27.
138. Lieberman R, Moy L. Estrogen receptor expression in melasma. results from; facial skin of affected patients. J Drugs Dermatol. 2008 May;7(5):463-5. PubMed; PMID. 18505139.
139. Thirion L, Piérard-Franchimont C, Piérard GE. Whitening effect of a; dermocosmetic formulation. a randomized double-blind controlled study on melasma.; Int J Cosmet Sci. 2006 Aug;28(4):263-7.
140. Ejaz A, Raza N, Iftikhar N, Muzzafar F. Comparison of 30% salicylic acid; with Jessner's solution for superficial chemical peeling in epidermal melasma. J ; Coll Physicians Surg Pak. 2008 Apr;18(4):205-8.
141. Keeling J, Cardona L, Benitez A, Epstein R, Rendon M. Mequinol 2%/tretinoin ; 0.01% topical solution for the treatment of melasma in men. a case series and; review of the literature. Cutis. 2008 Feb;81(2):179-83. Review.
142. Garg VK, Sarkar R, Agarwal R. Comparative evaluation of beneficiary effects ; of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of ; melasma with glycolic acid peels. Dermatol Surg. 2008 Aug;34(8):1032-9;; discussion 1340. Epub 2008 Apr 22.
143. Hernández-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, ; Moncada B. Solar elastosis and presence of mast cells as key features in the; pathogenesis of melasma. Clin Exp Dermatol. 2008 May;33(3):305-8.
144. Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on; quality of life in a sample of women living in southern Brazil. J Eur Acad; Dermatol Venereol. 2008 Jun;22(6):655-62. Epub 2008 Apr 10.
145. Verallo-Rowell VM, Pua JM, Bautista D. Visible light photopatch testing of; common photocontactants in female filipino adults with and without melasma. a; cross-sectional study. J Drugs Dermatol. 2008 Feb;7(2):149-56.
146. Li YH, Chen JZ, Wei HC, Wu Y, Liu M, Xu YY, Dong GH, Chen HD. Efficacy and; safety of intense pulsed light in treatment of melasma in Chinese patients.; Dermatol Surg. 2008 May;34(5):693-700; discussion 700-1. Epub 2008 Mar 3.
147. Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of; melasma after fractional resurfacing. Lasers Surg Med. 2008 Feb;40(2):134-8.;
148. Scherdin U, Bürger A, Bielfeldt S, Filbry A, Weber T, Schölermann A,; Wigger-Alberti W, Rippke F, Wilhelm KP. Skin-lightening effects of a new face; care product in patients with melasma. J Cosmet Dermatol. 2008 Mar;7(1):68-75.;
149. Grimes PE. An efficacy study of 3 commercially available hydroquinone 4%; treatments for melasma. Cutis. 2007 Dec;80(6):497-502.
150. Karsai S, Raulin C. [Fractional photothermolysis. a new option for treating ; melasma?]. Hautarzt. 2008 Feb;59(2):92-100. Review. German.
151. Taub AF. Fractionated delivery systems for difficult to treat clinical; applications. acne scarring, melasma, atrophic scarring, striae distensae, and; deep rhytides. J Drugs Dermatol. 2007 Nov;6(11):1120-8. Review.
152. Naito SK. Fractional photothermolysis treatment for resistant melasma in; Chinese females. J Cosmet Laser Ther. 2007 Sep;9(3):161-3.
153. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J; Cosmet Dermatol. 2007 Sep;6(3):195-202. Review.
154. Kalla G, Garg A, Kachhawa D. Chemical peeling--glycolic acid versus; trichloroacetic acid in melasma. Indian J Dermatol Venereol Leprol. 2001; Mar-Apr;67(2):82-4.
155. Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutical approaches in; melasma. Dermatol Clin. 2007 Jul;25(3):337-42, viii.
156. Kar HK. Efficacy of beta-carotene topical application in melasma. an open; clinical trial. Indian J Dermatol Venereol Leprol. 2002 Nov-Dec;68(6):320-2.;
157. Sawhney M, Anand R. Chronic pelvic inflammatory disease and melasma in; women. Indian J Dermatol Venereol Leprol. 2003 May-Jun;69(3):251-2.
158. Kar HK. Efficacy of beta-carotene topical application in melasma--an open; clinical trial. Indian J Dermatol Venereol Leprol. 2003 Mar-Apr;69(2):92-4.;
159. Bain S. Physical signs for the general dental practitioner. Case 45.; Melasma. Dent Update. 2007 Jun;34(5):316.
160. Soliman MM, Ramadan SA, Bassiouny DA, Abdelmalek M. Combined trichloroacetic; acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the; treatment of melasma. a comparative study. J Cosmet Dermatol. 2007; Jun;6(2):89-94.
161. Khemis A, Kaiafa A, Queille-Roussel C, Duteil L, Ortonne JP. Evaluation of; efficacy and safety of rucinol serum in patients with melasma. a randomized; controlled trial. Br J Dermatol. 2007 May;156(5):997-1004. Epub 2007 Mar 28.;
162. Cestari T, Adjadj L, Hux M, Shimizu MR, Rives VP. Cost-effectiveness of a; fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with; hydroquinone alone in the treatment of melasma. J Drugs Dermatol. 2007; Feb;6(2):153-60.
163. Werlinger KD, Guevara IL, González CM, Rincón ET, Caetano R, Haley RW,; Pandya AG. Prevalence of self-diagnosed melasma among premenopausal Latino women ; in Dallas and Fort Worth, Tex. Arch Dermatol. 2007 Mar;143(3):424-5.
164. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R.; Melasma and its impact on health-related quality of life in Hispanic women. J; Dermatolog Treat. 2007;18(1):5-9. Review.
165. Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J ; Dermatol Sci. 2007 May;46(2):111-6. Epub 2007 Mar 23.
166. Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison; of triple combination cream and hydroquinone 4% cream for the treatment of; moderate to severe facial melasma. J Cosmet Dermatol. 2007 Mar;6(1):36-9.
167. Scheinfeld NS. Melasma. Skinmed. 2007 Jan-Feb;6(1):35-7.
168. Erbil H, Sezer E, Taştan B, Arca E, Kurumlu Z. Efficacy and safety of serial; glycolic acid peels and a topical regimen in the treatment of recalcitrant; melasma. J Dermatol. 2007 Jan;34(1):25-30.
169. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as; a new therapeutic modality in melasma in comparison to Jessner's solution; chemical peels. Dermatol Surg. 2006 Dec;32(12):1429-36.
170. Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials; in melasma. Pigmentation Disorders Academy. Br J Dermatol. 2006 Dec;156 Suppl; 1:21-8.
171. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, Rêgo VR,; Mendes AM, Filho JW, Junqueira H. Validation of a melasma quality of life; questionnaire for Brazilian Portuguese language. the MelasQoL-BP study and; improvement of QoL of melasma patients after triple combination therapy. Br J; Dermatol. 2006 Dec;156 Suppl 1:13-20.
172. Levy JL, Pons F, Agopian L, Besson R. A double-blind controlled study of a; nonhydroquinone bleaching cream in the treatment of melasma. J Cosmet Dermatol.; 2005 Dec;4(4):272-6.
173. Zawar VP, Mhaskar ST. Exogenous ochronosis following hydroquinone for; melasma. J Cosmet Dermatol. 2004 Dec;3(4):234-6.
174. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma. a review of; clinical trials. J Am Acad Dermatol. 2006 Dec;55(6):1048-65. Epub 2006 Sep 28.; Review.
175. Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and; postinflammatory hyperpigmentation. Skin Therapy Lett. 2006 Nov;11(9):1-6.; Review.
176. Torok HM. A comprehensive review of the long-term and short-term treatment; of melasma with a triple combination cream. Am J Clin Dermatol. 2006;7(4):223-30.; Review.
177. Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina; patients. cross-cultural adaptation and validation of a quality-of-life; questionnaire in Spanish language. J Am Acad Dermatol. 2006 Jul;55(1):59-66. Epub; 2006 May 2.
178. Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, Park YM. Localized; intradermal microinjection of tranexamic acid for treatment of melasma in Asian; patients. a preliminary clinical trial. Dermatol Surg. 2006 May;32(5):626-31.;
179. Piamphongsant T. Phenol-castor oil. modified peel for dermal melasma.; Dermatol Surg. 2006 May;32(5):611-7; discussion 617.
180. Kang HY, Hwang JS, Lee JY, Ahn JH, Kim JY, Lee ES, Kang WH. The dermal stem ; cell factor and c-kit are overexpressed in melasma. Br J Dermatol. 2006; Jun;154(6):1094-9.
181. Yoshimura K, Sato K, Aiba-Kojima E, Matsumoto D, Machino C, Nagase T, Gonda ; K, Koshima I. Repeated treatment protocols for melasma and acquired dermal; melanocytosis. Dermatol Surg. 2006 Mar;32(3):365-71.
182. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am; Acad Dermatol. 2006 May;54(5 Suppl 2):S272-81. Review.
183. Shin JH, Kang WH. Two cases of melasma with unusual histopathologic; findings. J Korean Med Sci. 2006 Apr;21(2):368-70.
184. Grimes P, Kelly AP, Torok H, Willis I. Community-based trial of a; triple-combination agent for the treatment of facial melasma. Cutis. 2006; Mar;77(3):177-84.
185. Costin GE, Birlea SA. What is the mechanism for melasma that so commonly; accompanies human pregnancy? IUBMB Life. 2006 Jan;58(1):55-7. Review. PubMed; PMID. 16540433.
186. Moin A, Jabery Z, Fallah N. Prevalence and awareness of melasma during; pregnancy. Int J Dermatol. 2006 Mar;45(3):285-8.
187. Marcus L. Treatment of hyperpigmentation-melasma with photodynamic therapy. ; J Drugs Dermatol. 2006 Feb;5(2 Suppl):9-11.
188. Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional; photothermolysis. a pilot study. Dermatol Surg. 2005 Dec;31(12):1645-50. PubMed; PMID. 16336881.
189. Rusciani A, Motta A, Rusciani L, Alfano C. Q-switched alexandrite; laser-assisted treatment of melasma. 2-year follow-up monitoring. J Drugs; Dermatol. 2005 Nov-Dec;4(6):770-4.
190. Abramovits W, Barzin S, Arrazola P. A practical comparison of; hydroquinone-containing products for the treatment of melasma. Skinmed. 2005; Nov-Dec;4(6):371-6. Review.
191. Dar NR, Shaheen, Mustafvi SA, Raza N. Cutaneous pseudolymphoma due to; topical application of 4% hydroquinone cream for melasma. J Coll Physicians Surg ; Pak. 2005 Aug;15(8):496-7.
192. Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, Jarret M, Rich P,; Pariser D, Tschen E, Martin D, Menter A, Weiss J. A large 12-month extension; study of an 8-week trial to evaluate the safety and efficacy of triple; combination (TC) cream in melasma patients previously treated with TC cream or; one of its dyads. J Drugs Dermatol. 2005 Sep-Oct;4(5):592-7.
193. Tannous ZS, Astner S. Utilizing fractional resurfacing in the treatment of; therapy-resistant melasma. J Cosmet Laser Ther. 2005 Mar;7(1):39-43.
194. Astaneh R, Farboud E, Nazemi MJ. 4% hydroquinone versus 4% hydroquinone,; 0.05% dexamethasone and 0.05% tretinoin in the treatment of melasma. a; comparative study. Int J Dermatol. 2005 Jul;44(7):599-601.
195. Perez MI. The stepwise approach to the treatment of melasma. Cutis. 2005; Apr;75(4):217-22.
196. Lonsdale-Eccles AA, Langtry JA. Melasma on the nape of the neck in a man.; Acta Derm Venereol. 2005;85(2):181-2.
197. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and; ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005; Apr;27(2):96-101.
198. Ting PT, Barankin B. Can you identify this condition? Melasma. Can Fam; Physician. 2005 Mar;51:353-5. Review.
199. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid as a new; therapeutic peeling agent in melasma. Dermatol Surg. 2005 Feb;31(2):149-54;; discussion 154.
200. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin; 0.05%, fluocinolone acetonide 0.01%. a safe and efficacious 12-month treatment; for melasma. Cutis. 2005 Jan;75(1):57-62.
201. Victor FC, Gelber J, Rao B. Melasma. a review. J Cutan Med Surg. 2004; Mar-Apr;8(2):97-102. Epub 2004 May 4. Review.
202. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in; the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004; Dec;74(6):362-8.
203. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J; Drugs Dermatol. 2004 Sep-Oct;3(5 Suppl):S27-34. Review.
204. Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the; treatment of refractory melasma in Asian persons. Dermatol Surg. 2004; Sep;30(9):1196-200.
205. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized; trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004; Aug;43(8):604-7.
206. Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with; effective treatment of facial melasma. the pigment trial. J Drugs Dermatol. 2004 ; Jul-Aug;3(4):377-81.
207. Negishi K, Kushikata N, Tezuka Y, Takeuchi K, Miyamoto E, Wakamatsu S. Study; of the incidence and nature of "very subtle epidermal melasma" in relation to; intense pulsed light treatment. Dermatol Surg. 2004 Jun;30(6):881-6; discussion; 886.
208. Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in ; the treatment of Melasma in dark-skinned patients. Dermatol Surg. 2004; May;30(5):756-60; discussion 760.
209. Menter A. Rationale for the use of topical corticosteroids in melasma. J; Drugs Dermatol. 2004 Mar-Apr;3(2):169-74.
210. Nanda S, Grover C, Reddy BS. Efficacy of hydroquinone (2%) versus tretinoin ; (0.025%) as adjunct topical agents for chemical peeling in patients of melasma.; Dermatol Surg. 2004 Mar;30(3):385-8; discussion 389.
211. Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults:; Part II. Melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic ; dermopathy, tinea versicolor, and postinflammatory hyperpigmentation. Am Fam; Physician. 2003 Nov 15;68(10):1963-8. Review.
212. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with ; 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J; Dermatol. 2003 Dec;42(12):966-72.
213. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S,; Feldman SR, Chren MM. Development and validation of a health-related quality of; life instrument for women with melasma. Br J Dermatol. 2003 Sep;149(3):572-7.;
214. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, ; Wieder JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N.; Efficacy and safety of a new triple-combination agent for the treatment of facial; melasma. Cutis. 2003 Jul;72(1):67-72.
215. Coleman WP 3rd, Brody HJ. Efficacy of low-strength glycolic acid application; in the treatment of melasma. Arch Dermatol. 2003 Jun;139(6):811; author reply; 811-2.
216. Huh CH, Seo KI, Park JY, Lim JG, Eun HC, Park KC. A randomized,; double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma.; Dermatology. 2003;206(4):316-20.
217. Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa D Jr. A; clinical, prospective, randomized, double-blind trial comparing skin whitening; complex with hydroquinone vs. placebo in the treatment of melasma. Int J; Dermatol. 2003 Feb;42(2):153-6.
218. Sarkar R, Jain RK, Puri P. Melasma in Indian males. Dermatol Surg. 2003; Feb;29(2):204.
219. Angsuwarangsee S, Polnikorn N. Combined ultrapulse CO2 laser and Q-switched ; alexandrite laser compared with Q-switched alexandrite laser alone for refractory; melasma. split-face design. Dermatol Surg. 2003 Jan;29(1):59-64.
220. Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid; peels in the treatment of melasma. Arch Dermatol. 2002 Dec;138(12):1578-82.;
221. Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream; monotherapy versus a sequential therapy in the treatment of melasma in; dark-skinned patients. Dermatology. 2002;205(3):249-54.
222. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid; peels with a topical regimen in the treatment of melasma in dark-skinned; patients. a comparative study. Dermatol Surg. 2002 Sep;28(9):828-32; discussion; 832.
223. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res.; 2002 Sep;16(6):567-71.
224. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma. a; preliminary report. J Dermatol. 2002 Aug;29(8):539-40.
225. Lee MH, Kim HJ, Ha DJ, Paik JH, Kim HY. Therapeutic effect of topical; application of linoleic acid and lincomycin in combination with betamethasone; valerate in melasma patients. J Korean Med Sci. 2002 Aug;17(4):518-23. PubMed; PMID. 12172049;
226. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, Sohn S, Im S. Melasma:; histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002; Feb;146(2):228-37.
227. Im S, Kim J, On WY, Kang WH. Increased expression of; alpha-melanocyte-stimulating hormone in the lesional skin of melasma. Br J; Dermatol. 2002 Jan;146(1):165-7.
228. Javaheri SM, Handa S, Kaur I, Kumar B. Safety and efficacy of glycolic acid ; facial peel in Indian women with melasma. Int J Dermatol. 2001 May;40(5):354-7.;
229. Guevara IL, Pandya AG. Melasma treated with hydroquinone, tretinoin, and a; fluorinated steroid. Int J Dermatol. 2001 Mar;40(3):212-5.
230. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion. a curative; treatment for melasma. Aesthetic Plast Surg. 2001 Mar-Apr;25(2):114-7. PubMed; PMID. 11349301.
231. Mandry Pagán R, Sánchez JL. Mandibular melasma. P R Health Sci J. 2000; Sep;19(3):231-4.
232. Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol.; 2000 Apr;39(4):299-301.
233. Sialy R, Hassan I, Kaur I, Dash RJ. Melasma in men. a hormonal profile. J; Dermatol. 2000 Jan;27(1):64-5.
234. Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol. 1999;455:491-9.
235. O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the arms associated with; hormone replacement therapy. Br J Dermatol. 1999 Sep;141(3):592-3.
236. Varma S, Roberts DL. Melasma of the arms associated with hormone replacement; therapy. Br J Dermatol. 1999 Sep;141(3):592.
237. Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma; in Thai patients. a vehicle-controlled clinical trial. J Med Assoc Thai. 1999; Sep;82(9):868-75.
238. Goh CL, Dlova CN. A retrospective study on the clinical presentation and; treatment outcome of melasma in a tertiary dermatological referral centre in; Singapore. Singapore Med J. 1999 Jul;40(7):455-8.
239. Nouri K, Bowes L, Chartier T, Romagosa R, Spencer J. Combination treatment; of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser. a; pilot study. Dermatol Surg. 1999 Jun;25(6):494-7.
240. Lim JT. Treatment of melasma using kojic acid in a gel containing; hydroquinone and glycolic acid. Dermatol Surg. 1999 Apr;25(4):282-4.
241. Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. ; Dermatol Surg. 1999 Feb;25(2):121-3.
242. Johnston GA, Sviland L, McLelland J. Melasma of the arms associated with; hormone replacement therapy. Br J Dermatol. 1998 Nov;139(5):932.
243. Piamphongsant T. Treatment of melasma. a review with personal experience.; Int J Dermatol. 1998 Dec;37(12):897-903. Review.
244. Kar S. Treatment of melasma innovating newer ideas. Indian J Dermatol; Venereol Leprol. 1999 Jan-Feb;65(1):48.
245. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients ; with combined topical agents (retinoic acid, hydroquinone and hydrocortisone):; clinical and histological studies. J Dermatol. 1998 Sep;25(9):587-96. PubMed; PMID. 9798345.
246. Hassan I, Kaur I, Sialy R, Dash RJ. Hormonal milieu in the maintenance of; melasma in fertile women. J Dermatol. 1998 Aug;25(8):510-2.
247. Tabata H, Yamakage A, Yamazaki S. Bandlike melasma mimicking linear morphea ; ("en coup de sabre" type). Cutis. 1998 Apr;61(4):225-6.
248. Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner's solution; versus glycolic acid. a comparison of clinical efficacy and evaluation of the; predictive ability of Wood's light examination. J Am Acad Dermatol. 1997; Apr;36(4):589-93.
249. Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian; women. Dermatol Surg. 1997 Mar;23(3):177-9.
250. Piérard GE. [How I treat... facial melasma]. Rev Med Liege. 1997; Feb;52(2):58-9. French.
251. O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Australas J; Dermatol. 1997 Feb;38(1):35-7. Review.
252. Aloi F, Solaroli C, Giovannini E. Actinic lichen planus simulating melasma. ; Dermatology. 1997;195(1):69-70.
253. Burke H, Carmichael AJ. Reversible melasma associated with tretinoin. Br J; Dermatol. 1996 Nov;135(5):862.
254. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or; kojic acid for the treatment of melasma and related conditions. Dermatol Surg.; 1996 May;22(5):443-7.
255. Breathnach AS. Melanin hyperpigmentation of skin. melasma, topical treatment; with azelaic acid, and other therapies. Cutis. 1996 Jan;57(1 Suppl):36-45.; Review.
256. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol.; 1995 Dec;131(12):1453-7. Review.
257. Kopera D, Hohenleutner U. Ruby laser treatment of melasma and; postinflammatory hyperpigmentation. Dermatol Surg. 1995 Nov;21(11):994. PubMed; PMID. 7582845.
258. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and; postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg; Oncol. 1994 Sep;20(9):592-7.
259. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM,; Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black; patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994; Jun;130(6):727-33.
260. Kanwar AJ, Dhar S, Kaur S. Treatment of melasma with potent topical; corticosteroids. Dermatology. 1994;188(2):170.
261. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ.; Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled,; clinical trial. Br J Dermatol. 1993 Oct;129(4):415-21.
262. al-Fouzan AS, Hassab-el-Naby HM. Melasma-like (pigmented) actinic lichen; planus. Int J Dermatol. 1992 Jun;31(6):413-5.
263. Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4%; hydroquinone cream. Int J Dermatol. 1991 Dec;30(12):893-5.
264. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent; for the melanoderma of patients with melasma. Arch Dermatol. 1991; Oct;127(10):1528-34.
265. Wolf R, Wolf D, Tamir A, Politi Y. Melasma. a mask of stress. Br J Dermatol.; 1991 Aug;125(2):192-3.
266. Rigoni C, Toffolo P, Serri R, Caputo R. [Use of a cream based on 20% azelaic; acid in the treatment of melasma]. G Ital Dermatol Venereol. 1989; Jan-Feb;124(1-2):I-VI. Italian.
267. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M.; Double-blind comparison of azelaic acid and hydroquinone in the treatment of; melasma. Acta Derm Venereol Suppl (Stockh). 1989;143:58-61.
268. Salman SM, Khallouf R, Zaynoun S. Actinic lichen planus mimicking melasma. A; clinical and histopathologic study of three cases. J Am Acad Dermatol. 1988; Feb;18(2 Pt 1):275-8.
269. Vázquez M, Maldonado H, Benmamán C, Sánchez JL. Melasma in men. A clinical; and histologic study. Int J Dermatol. 1988 Jan-Feb;27(1):25-7.
270. Piquero Martín J, Rothe de Arocha J, Beniamini Loker D. [Double-blind; clinical study of the treatment of melasma with azelaic acid versus; hydroquinone]. Med Cutan Ibero Lat Am. 1988;16(6):511-4. Spanish.
271. Hughes BR. Melasma occurring in twin sisters. J Am Acad Dermatol. 1987; Nov;17(5 Pt 1):841.
272. Abarca J, Odilla Arrollo C, Blanch S, Arellano G. [Melasma in pregnancy:; reduction of its appearance with the use of a broad-spectrum photoprotective; agent]. Med Cutan Ibero Lat Am. 1987;15(3):199-203. Spanish.
273. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the; treatment of melasma. J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):894-9.
274. Lutfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzalez EA, Villemur JA,; Mazzini MA, Niepomniszcze H. Association of melasma with thyroid autoimmunity and; other thyroidal abnormalities and their relationship to the origin of the; melasma. J Clin Endocrinol Metab. 1985 Jul;61(1):28-31.
275. Pérez M, Sánchez JL, Aguiló F. Endocrinologic profile of patients with; idiopathic melasma. J Invest Dermatol. 1983 Dec;81(6):543-5.
276. Vázquez M, Sánchez JL. The efficacy of a broad-spectrum sunscreen in the; treatment of melasma. Cutis. 1983 Jul;32(1):92, 95-6.
277. Sánchez JL, Vázquez M. A hydroquinone solution in the treatment of melasma. ; Int J Dermatol. 1982 Jan-Feb;21(1):55-8.
278. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC Jr.; Melasma. a clinical, light microscopic, ultrastructural, and immunofluorescence; study. J Am Acad Dermatol. 1981 Jun;4(6):698-710.
279. Witkiewicz IM, Neering H. [Facial melanosis (melasma)]. Ned Tijdschr; Geneeskd. 1981 Apr 18;125(16):609-11. Dutch.
280. Milstein HG. 5-Fluorouracil as an aid in management of acne and melasma. J; Am Acad Dermatol. 1981 Jan;4(1):97-8.
281. Gano SE, Garcia RL. Topical tretinoin, hydroquinone, and betamethasone; valerate in the therapy of melasma. Cutis. 1979 Feb;23(2):239-41.
282. Brun R, Laugier P. [Guinea pig nipple as a model for the investigation of; melasma (author's transl)]. Dermatologica. 1979;159(3):210-6. French. PubMed; PMID. 478059.
283. Jackson R. A statement on melasma. Can Med Assoc J. 1977 Jun; 4;116(11):1224-6.
284. Neering H. Treatment of melasma (chloasma) by local application of a steroid; cream. Dermatologica. 1975;151(6):349-53.
285. Hammer CJ. Melasma induced by oral contraceptive drugs. Northwest Med. 1968 ; Mar;67(3):251-4.
286. Peterson WC Jr. Melasma (chloasma). Minn Med. 1968 Jan;51(1):115-6. PubMed; PMID. 5636219.
287. Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967 Feb; 27;199(9):601-5.
288. Resnik SS. Melasma and other skin manifestations or oral contraceptives.; Trans N Engl Obstet Gynecol Soc. 1967;21:101-7.
289. Resnik SS. Combined or sequential oral contraceptives may cause melasma; without total regression. JAMA. 1966 Jul 4;197(1):Suppl:25.
290. ZADURA J. [Intestinal hemorrhagic melasma in shoats]. Med Weter. 1950; Apr;6(4):225-6. Undetermined Language.

No comments:

Post a Comment

Your comment will appear after it is approved